New preclinical data confirming AsiDNA™’s abilities to protect from #anticancer treatment toxicity and fight #tumor resistance presented during poster and oral sessions at the American Association for Cancer Research Annual Meeting (#AACR)
More info: https://t.co/XBvIFxo2LP
We participate in the DDR, ATR & PARP Inhibitors Summit 2022 !
Wael Jdey, Lead Scientist at #ONXEO will present today at 8AM EST and at 9:30AM EST
Click here for more info 👉 https://t.co/X0Tk86w2hM
#event#digitalevent#PARPinhibitors#Resistance
AsiDNA™’s pioneering data highlighted at the EACR-AstraZeneca Virtual Conference during two dedicated sessions
Click here for more infos 👉 https://t.co/sDT9voCanp
#ONXEO#eacrAstraZeneca@AstraZeneca
#Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector
More information 👉 https://t.co/t9wfMt9ndz
#Onxeo Receives Notice of Allowance for a New Patent
Broadening the Protection of AsiDNA™ in combination
with a PARP Inhibitor in the United States until 2036
More informations 👉 https://t.co/7bWO9SrgDc
#Onxeo Reports FYR 2020 and Provides Business Update: financial visibility until end-2022, enabling the expansion of clinical and industrial development of #AsiDNA™
[INTERVIEW]
Retrouvez Judith Greciet, Directrice Générale d'@Onxeo_, qui commente les récents développements d’#Onxeo et explique les raisons de l'augmentation de capital en cours ➡️ https://t.co/xRGXmJR52L
#Interview#Onxeo
Pour la semaine nationale de lutte contre le #cancer, nous vous présentons @Onxeo_ ➡️ une #biotech qui conçoit et développe de nouveaux #médicaments contre le cancer en ciblant les fonctions de réparation de l'ADN des #tumeurs.
Plus d'infos 👉 https://t.co/j4DbSqWaHD